source
- Pierre Fabre aligns with FDA on resubmission of Ebvallo cell therapyPierre Fabre Laboratories announced that it has reached an agreement with the U.S. Food and Drug Administration on a new path for its cell therapy Ebvallo, which had been rejected twice. The FDA w…
- Capricor sues Japanese partner over botched Duchenne therapy launch and pricing concernsCapricor Therapeutics has filed a lawsuit against its Japanese collaborator Nippon Shinyaku and its subsidiary NS Pharma. The biotech alleges the partners mishandled preparations for the launch of…